Search results
Results from the WOW.Com Content Network
Breslow's depth is determined by using an ocular micrometer at a right angle to the skin to directly measure the depth to which tumor cells have invaded the skin. Breslow's depth is measured from the granular layer of the epidermis down to the deepest point of invasion (sometimes involving detached nests of cells).
Clinical lesions will only be considered measurable when they are superficial (e.g., skin nodules and palpable lymph nodes). For the case of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is recommended.
The Bortle dark-sky scale (usually referred to as simply the Bortle scale) is a nine-level numeric scale that measures the night sky's brightness of a particular location. It quantifies the astronomical observability of celestial objects and the interference caused by light pollution .
After removal of the cancer, closure of the skin for patients with a decreased amount of skin laxity involves a split-thickness skin graft. A donor site is chosen and enough skin is removed so that the donor site can heal on its own. Only the epidermis and a partial amount of dermis is taken from the donor site which allows the donor site to heal.
The total magnitude is a measure of the brightness of an extended object such as a nebula, cluster, galaxy or comet. It can be obtained by summing up the luminosity over the area of the object. Alternatively, a photometer can be used by applying apertures or slits of different sizes of diameter. [1]
John E. Bortle is an American amateur astronomer. He is best known for creating the Bortle scale to quantify the darkness of the night sky. Bortle has made a special study of comets. He has recorded thousands of observations relating to more than 300 comets. From 1977 until 1994 he authored the monthly '"Comet Digest" in Sky and Telescope magazine.
The Common Terminology Criteria for Adverse Events (CTCAE), [1] formerly called the Common Toxicity Criteria (CTC or NCI-CTC), are a set of criteria for the standardized classification of adverse events of drugs and treatment used in cancer therapy. The CTCAE system is a product of the US National Cancer Institute (NCI).
Grading in cancer is distinguished from staging, which is a measure of the extent to which the cancer has spread. Pathology grading systems classify the microscopic cell appearance abnormality and deviations in their rate of growth with the goal of predicting developments at tissue level (see also the 4 major histological changes in dysplasia ).